Publication

Metal-based antitumour drugs in the post genomic era

Paul Joseph Dyson
2006
Journal Articles

Abstract

The discovery of new metal-based antitumor drugs, whether cisplatin derivs. or those based on other metals, has been largely based on cell viability assays (IC50 values) and compds. that bind to DNA. This approach has been applied for more than 30 years during which time very few new drugs have entered clin. use. In this article we discuss what the future holds for metal-based drugs, in particular anti-metastasis drugs, in these enlightened times of the post genomic era.

Official source

Graph Chat

Chat with Graph Search

Ask any question about EPFL courses, lectures, exercises, research, news, etc. or try the example questions below.

DISCLAIMER: The Graph Chatbot is not programmed to provide explicit or categorical answers to your questions. Rather, it transforms your questions into API requests that are distributed across the various IT services officially administered by EPFL. Its purpose is solely to collect and recommend relevant references to content that you can explore to help you answer your questions.

Metal-based antitumour drugs in the post genomic era

Chat with Graph Search

Cyclic Peptides for Drug Development

The predictive capacity of in vitro preclinical models to evaluate drugs for the treatment of retinoblastoma

Alchemical analysis of FDA approved drugs